<DOC>
	<DOCNO>NCT01695356</DOCNO>
	<brief_summary>Melasma acquire discoloration skin characterize brown colour change commonly face . The duration double-blind clinical trial 12 week . The control group receive treatment topical Hydroquinone ( 4 % ) Broad spectrum UV sunscreen . The experimental group , 4 % topical hydroquinone Broad spectrum UV-visible light sunscreen . Visible light melanotic property avoid part treatment melasma patient . The estimated number subject recruit randomized study least 25 per group . The purpose study determine difference improvement two sunscreen type . Melasma Area Severity Index ( MASI ) score assess begin study week 4 , 8 , 12 . Photographs , colorimetry histological assessment also evaluate . Occurrence adverse effect also record .</brief_summary>
	<brief_title>Ultraviolet UV-Visible Light Photoprotection Treatment Melasma</brief_title>
	<detailed_description>Melasma common acquire hypermelanosis dark skin population , usually characterize symmetrical , irregular macule occur photo-exposed area face . Treatment sunscreens depigmenting compound hydroquinone , still gold standard condition . Visible light pigment property could interfere treatment melasma patient . So , primary objective study compare depigmenting adjuvant effect use UV-visible block sunscreen UV sunscreen . Patients include study randomly assign receive one sunscreen type , use 12 week . The sun block agent apply affected region every 3 hour 8AM 5PM . The evaluation clinical improvement do blind modality mean MASI score , Global Physician Assessment , well colorimetry histological melanin content . Evaluations hold visit 4 , 8 12 week . Skin biopsy take onset 12 week . At end study , data compare concern former parameter . All side effect record analyse .</detailed_description>
	<mesh_term>Melanosis</mesh_term>
	<mesh_term>Sunscreening Agents</mesh_term>
	<mesh_term>Titanium dioxide</mesh_term>
	<mesh_term>Zinc Oxide</mesh_term>
	<mesh_term>Terephthalylidene dicamphor sulfonic acid</mesh_term>
	<mesh_term>Avobenzone</mesh_term>
	<mesh_term>Octylmethoxycinnamate</mesh_term>
	<mesh_term>Oxybenzone</mesh_term>
	<mesh_term>Benzophenone</mesh_term>
	<criteria>Signed informed consent Women 25 year age Dermatologic diagnostic melasma Phototype III Pregnant breastfeed Postbirth , abortion past 6 month Having endocrine autoimmune disease Under hormonal therapy kind include contraceptive it´s use past 6 month Currently treatment melasma include sunscreen Currently radiation therapy , chemotherapy , immunosuppressant kind phototherapy it´s use past 6 month Having use consume photosensitize substance , oral topical</criteria>
	<gender>Female</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Melasma</keyword>
	<keyword>sunscreen</keyword>
	<keyword>visible light</keyword>
	<keyword>ultraviolet light</keyword>
</DOC>